Heterogeneity in Treatment Effects of Reduced Versus Standard Dose of Cabazitaxel in Metastatic Castration‐Resistant Prostate Cancer
The OS effect of C25 versus C20 may vary based on baseline characteristics in post-docetaxel mCRPC. Patients with extensive treatment history and disease burden may benefit more from C25.
Authors
- Wataru Fukuokaya (ORCID: https://orcid.org/0000-0003-1044-912X)
- P. Rajwa
- Shahrokh F. Shariat
- Takafumi Yanagisawa
- Keiichiro Mori
- Takahiro Kimura
- Kagenori Ito
- Akihiro Hirakawa
Institutions
- Jikei University School of Medicine (JP)
- Medical University of Silesia (PL)
- Cornell University (US)
- Charles University (CZ)
- Comprehensive Cancer Center Vienna (AT)
- Karl Landsteiner Society (AT)
- University College London (GB)
- Medical University of Vienna (AT)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2026-01-01
- DOI
- https://doi.org/10.1002/cam4.71507
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sanofi
- Narodowa Agencja Wymiany Akademickiej
- Agencja Badań Medycznych